REFRENCES
Ahsani, Z., Mohammadi‑Yeganeh, S., Kia, V., Karimkhanloo, H., Zarghami ,N., Paryan ,M.(2017) WNT1 gene from WNT signaling pathway is a direct target of miR‑122 in hepatocellular carcinoma. Appl Biochem Biotechnol 181: 884‑ 897.
Akuta, N., Kawamura, Y., Suzuki, F., Saitoh ,S., Arase, Y., Kunimoto H., Sorin, Y., Fujiyama, S., Sezaki ,H., Hosaka, T., et al.(2016) Impact of circulating miR‑122 for histological features and hepatocellular carcinoma of nonalcoholic fatty liver disease in Japan. Hepatol Int 10: 647‑656.
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A., Jemal, A. (2018) Global cancer (statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424.
Cascio, S., D’Andrea, A., Ferla, R., Surmacz, E., Gulotta, E., Amodeo, V., Bazan, V., Gebbia, N., Russo, A.(2010) miR-20b Modulates VEGF Expression by Targeting HIF-1 Alpha and STAT3 in MCF-7 Breast Cancer Cells. J. Cell. Physiol. 224, 242–249.
Chen ,Z., Xu, S., Xu, W., Huang, J., Zhang ,GU., Lei, L., Shao, X., Wang, X. (2015) Expression of cluster of differentiation 34 and vascular endothelial growth factor in breast cancer, and their prognostic significance, Oncol Lett. 723-729
Cohen, P. (2001) Protein kinases-the major drug targets of the twenty-first century. Nat. Rev. Drug Discovery 1: 309–315.
Colozza, M., de Azambuja, E., Personeni, N., Lebrun, F., Piccart, M.J., Cardoso, F. (2007) Achievements in Systemic Therapies in the Pregenomic Era in Metastatic Breast Cancer. Onc. 12, 253–270.
Duc Duy ,Vo., Cathy, Staedel., Laura ,Zehnacker., Rachid, Benhida.,Fabien ,Darfeuille., and Maria, Duca.(2014) Targeting the Production of Oncogenic MicroRNAs with Multimodal Synthetic Small Molecules. ACS Chem. Biol. 9, 711−721
Emile ,N.,Van Meter Jackline ,A.,Onyango Kelly, A.Teske. (2020) A review of currently identified small molecule modulators of microRNA function. European Journal of Medicinal Chemistry, Volume 188,  112008
Eroles, P., Bosch, A., Pérez-fidalgo, J.A., Lluch, A. (2012) Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways. Cancer Treat. Rev. 38, 698–707.
Fan-Wei ,Peng.,Da-Ke, Liu.,Qing-Wen, Zhang.,Yun-Gen ,Xu &Lei, Shi. (2012-2016) VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review. Expert Opinion on Therapeutic Patents Volume 27, 2017 - 987-1004
Ferrara, N., Gerber ,H.P., LeCouter, J. (2003) The biology of VEGF and its receptors. Nat Med. 9, 669–676.
Fox, S.B., Generali, D.G., Harris, A.L. (2007) Breast tumour angiogenesis. Breast Cancer Res 9: 216. doi: 10.1186/bcr1796 PMID: 18190723.
Hamam, R.,Hamam, D., Alsaleh, K.A., Kassem, M.,Zaher, W., Alfayez, M., Aldahmash, A., Alajez, N.M.(2017) Circulating microRNAs in breast cancer: Novel diagnostic and prognostic biomarkers. Cell Death Dis. 8, e3045.
Holmes, K., Roberts, O. L., Thomas, A. M. & Cross, M. J. (2007) Vascular endothelial growth factor receptor-2: Structure, function, intracellular signalling and therapeutic inhibition. Cellular Signalling 19, 2003–2012.
Hopcraft ,S.E., Azarm, K.D., Israelow, B., Lévêque, N., Schwarz, M.C., Hsu, T.H., Chambers, M.T., Sourisseau, M., Semler, B.L., Evans, M.J.(2015) Viral determinants of miR‑122‑independent hepatitis C virus replication. mSphere 1: 1.
Howlader, N., Noone, A. M.,Krapcho, M., Neyman, N., Aminou, R., ltekruse, S. F.,Kosary, C. L., Ruhl, J., Tatalovich, Z., Cho, H., et al. (2009) SEER Cancer Statistics Review,1975-2009, Vintage Populations. Natl. Cancer Inst. 2012. Bethesda, MD.
Hu, F., Xu, P., Sun, B., Xiao, Z.(2017) Differences in the MicroRNA profiles of subcutaneous adipose ‑ derived stem cells and omental adipose ‑derived stem cells. Gene 625: 55 ‑63.
Hu, J., Cheng, Y., Li, Y., Jin, Z., Pan, Y., Liu, G., Fu, S., Zhang, Y., Feng, K., Feng, Y.(2014) microRNA-128 Plays a Critical Role in Human Non-Small Cell Lung Cancer Tumourigenesis, Angiogenesis and Lymphangiogenesis by Directly Targeting Vascular Endothelial Growth Factor-C. Eur. J. Cancer. 50, 2336–2350.
Isidro, X., Perez‐Añorve, Claudia ,H., Gonzalez‐De , Rosa.,  Ernesto Soto‐Reyes.,  Fredy, O., Beltran‐Anaya, Oscar Del Moral‐Hernandez, Marisol Salgado‐Albarran, et al. (2019) New insights into radioresistance in breast cancer identify a dual function of miR‐122 as a tumor suppressor and oncomiR. Mol Oncol. 13, 1249–1267.
Jia, D., Hasso, S.M., Chan, J., Filingeri ,D., D’Amore, P.A., Rice, L., et al.( 2013) Transcriptional repression of VEGF by ZNF24: mechanistic studies and vascular consequences in vivo. Blood 121: 707–715. doi: 10.1182/blood-2012-05-433045 PMID: 23212515.
Kian, R., Moradi, S.,Ghorbian, S. (2018) Role of components of microRNA machinery in carcinogenesis. Exp. Oncol. 40, 2–9.
Lala, P. K., Nandi, P., Majumder, M. (2018) Roles of Prostaglandins in Tumor Associated Lymphangiogenesis with Special Reference to Breast Cancer. Cancer Metastasis Rev. 37, 1.
Lazarus, H., Tegeler, W., Mazzone, H. M., Leroy, J. G., Boone, B. A., & Foley, G. E.(1966) Determination of sensitivity of individual biopsy specimens to potential inhibitory agents: evaluation of some explant culture methods as assay systems. Cancer Chemotherapy Reports, 50(8), 543–555.
Liu, X.,Guan, Y., Wang, L.,Niu, Y.(2017) MicroRNA-10b Expression in Node-Negative Breast Cancer-Correlation with Metastasis and Angiogenesis. Oncol. Lett. 14, 5845–5852.
Lou, W., Liu, J., Gao, Y.,Zhong, G., Chen, D., Shen, J., Bao, C., Xu, L., Pan, J., Cheng, J.,et al. (2017) MicroRNAs in Cancer Metastasis and Angiogenesis. Oncotarget 8, e115787.
Maae, E., Olsen, D.A., Steffensen, K.D., Jakobsen, E.H., Brandslund, I., Sørensen, F.B., et al. (2012). Prognostic impact of placenta growth factor and vascular endothelial growth factor A in patients with breast cancer. Breast Cancer Res Treat 133: 257–265. doi: 10.1007/s10549-012-1957-0 PMID: 22270936.
Maierthaler, M., Benner, A., Hoffmeister, M., Surowy, H., Jansen, L., Knebel, P., Chang‑Claude, J., Brenner, H., Burwinkel, B.(2017) Plasma miR‑122 and miR‑200 family are prognostic markers in colorectal cancer. Int J Cancer 140: 176‑187.
Musumeci, F., Radi, M., Brullo, C., et al. (2012) Vascular endothelial growth factor (VEGF) receptors: drugs and new inhibitors. J Med Chem. 55(24):10797–10822.
Olsson, A. K., Dimberg, A., Kreuger, J., Claesson-Welsh L. (2006) VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol. 7:359–371
Otrock, Z.K., Mahfouz, R.A.R., Makarem, J.A., Shamseddine, A.I. (2007) Understanding the Biology of Angiogenesis: Review of the most Important Molecular Mechanisms. Blood Cells Mol. Dis. 39, 212–220.
Pan, C., Wang, X., Shi, K., Zheng, Y., Li, J., Chen, Y., Jin, L., Pan ,Z.(2016) miR‑122 reverses the doxorubicin ‑resistance in hepatocellular carcinoma cells through regulating the tumor metabolism. PLoS One 11: e0152090.
Pyakurel, D., Karki, S., & Agrawal, C. (2014) A study on microvascular density in breast carcinoma. Journal of Pathology of Nepal, 4(7), 570-575.
Qin, H., Sha, J., Jiang, C., Gao, X., Qu ,L., Yan, H., Xu, T., Jiang, Q., Gao, H.(2015) miR‑122 inhibits metastasis and epithelial‑mesenchymal transition of non‑small‑cell lung cancer cells. Onco Targets Ther 8: 3175‑3184.
Ran, S., Volk, L., Hall, K., Flister, M.J.(2010) Lymphangiogenesis and Lymphatic Metastasis in Breast Cancer. Pathophysiology 17, 229–251.
Sebolt-Leopold, J.S .(2006) Mechanisms of drug inhibition of signalling molecules. Nature 441: 457-462
Shibuya, M.(2011) Vascular Endothelial Growth Factor (VEGF) and its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies. Genes Cancer 2, 1097–1105.
Song, S., Ajani, J.A.(2013) The role of microRNAs in cancers of the upper gastrointestinal tract. Nature Rev. Gastroenterol. Hepatol. 10, 109–118.
Svoronos, A.A., Engelman, D.M., Slack, F.J.(2016) Oncomir or tumor suppressor? The duplicity of microRNAs in cancer. Cancer Res. 76, 3666–3670.
Tao, L., Chu, L., Wang, L.I., Moy, L., Brammer, M., Song, C., Green, M., Kurian, A.W., Gomez, S., Clarke, C.A. (2016) Occurrence and outcome of de novo metastatic breast cancer by subtype in a large, diverse population. Cancer Causes Control. 27, 1127–1138.
Uzzan, B., Nicolas, P., Cucherat, M., Perret, G.Y. (2004) Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res ;64:2941^55.
Von Felden, J., Heim ,D., Schulze, K., Krech, T., Ewald, F., Nashan, B., Lohse, AW., Wege, H.(2017) High expression of micro RNA‑135A in hepatocellular carcinoma is associated with recurrence within 12 months after resection. BMC Cancer 17: 60, 2017
Wang, C., Zheng, X ., Shen, C., Shi, Y.(2012) MicroRNA-203 suppresses cell proliferation and migration by targeting BIRC5 and LASP1 in human triple-negative breast cancer cells. J Exp Clin Cancer Res. 31: 58.
Williams, J. I., Weitman, S., Gonzalez, C. M., Jundt, C. H., Marty, J., Stringer, S. D., Von Hoff, D. D.( 2001) Squalamine treatment of human tumors in nu/nu mice enhances platinum-based chemotherapies. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 7(3), 724–733.
Young, D.D., Connelly, C.M., Grohmann, C., Deiters, A. Small molecule modifiers of MicroRNA miR-122 function for the treatment of hepatitis C Virus infection and hepatocellular carcinoma.. Journal of the American Chemical Society 132, (23), 7976-7981
Zhong ,Hua.,  Qing ,Lv., Wenbin, Ye., Chung-Kwun Amy Wong,    and Yaou ,Zhang. (2006) PLoS One. 2006; 1(1): e116.
Zorgetto ,V,A., Silveira ,G.G., Oliveira-Costa, J.P., Soave ,D.F., Soares, F.A., and Ribeiro-Silva, A.(2013) The relationship between lymphatic vascular density and vascular endothelial growth factor A (VEGF-A) expression with clinical-pathological features and survival in pancreatic adenocarcinomas. Diagn Pathol. 8:170.